AIG
NBIX icon

American International Group’s Neurocrine Biosciences NBIX Stock Holding History

American International Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-132,511
Closed -$18.3M – 1722
2024
Q1 		$18.3M Sell
132,511
-1,032
-0.8% -$141K 0.07% 174
2023
Q4 		$17.6M Sell
133,543
-4,895
-4% -$563K 0.07% 162
2023
Q3 		$15.6M Sell
138,438
-9,664
-7% -$1.02M 0.1% 169
2023
Q2 		$14M Sell
148,102
-1,385
-0.9% -$135K 0.09% 213
2023
Q1 		$15.1M Sell
149,487
-699
-0.5% -$72.7K 0.1% 179
2022
Q4 		$17.9M Sell
150,186
-1,220
-0.8% -$143K 0.13% 141
2022
Q3 		$16.1M Sell
151,406
-6,986
-4% -$709K 0.12% 145
2022
Q2 		$15.4M Sell
158,392
-3,100
-2% -$286K 0.1% 170
2022
Q1 		$15.1M Buy
161,492
+304
+0.2% +$25.8K 0.08% 238
2021
Q4 		$13.7M Sell
161,188
-2,597
-2% -$239K 0.07% 325
2021
Q3 		$15.7M Sell
163,785
-4,966
-3% -$469K 0.08% 228
2021
Q2 		$16.4K Sell
168,751
-2,461
-1% -$236K 0.06% 286
2021
Q1 		$16.6K Buy
171,212
+168,902
+7,312% +$17.7M 0.06% 275
2020
Q4 		$221 Sell
2,310
-97
-4% -$9.37K ﹤0.01% 2230
2020
Q3 		$232K Sell
2,407
-109
-4% -$12.6K ﹤0.01% 2051
2020
Q2 		$307K Buy
2,516
+438
+21% +$48.4K ﹤0.01% 1861
2020
Q1 		$180K Sell
2,078
-41
-2% -$4.01K ﹤0.01% 1957
2019
Q4 		$228K Sell
2,119
-90
-4% -$9.42K ﹤0.01% 2138
2019
Q3 		$199K Hold
2,209
– – ﹤0.01% 2169
2019
Q2 		$187K Buy
2,209
+129
+6% +$10.6K ﹤0.01% 2273
2019
Q1 		$183K Sell
2,080
-74
-3% -$6.18K ﹤0.01% 2259
2018
Q4 		$154K Hold
2,154
– – ﹤0.01% 2341
2018
Q3 		$265K Hold
2,154
– – ﹤0.01% 2260
2018
Q2 		$212K Buy
2,154
+133
+7% +$11.9K ﹤0.01% 2318
2018
Q1 		$168K Sell
2,021
-48
-2% -$4.05K ﹤0.01% 2366
2017
Q4 		$161K Buy
+2,069
New +$141K ﹤0.01% 2449
2017
Q3 		– Sell
-2,118
Closed -$97K – 2945
2017
Q2 		$97K Buy
2,118
+161
+8% +$7.81K ﹤0.01% 2748
2017
Q1 		$85K Sell
1,957
-74
-4% -$3.17K ﹤0.01% 2670
2016
Q4 		$79K Hold
2,031
– – ﹤0.01% 2726
2016
Q3 		$103K Sell
2,031
-88
-4% -$4.38K ﹤0.01% 2578
2016
Q2 		$96.3K Sell
2,119
-47,849
-96% -$2.2M ﹤0.01% 2629
2016
Q1 		$1.98M Sell
49,968
-1,380
-3% -$54.8K 0.01% 1117
2015
Q4 		$2.9M Sell
51,348
-187
-0.4% -$9.5K 0.01% 974
2015
Q3 		$2.05M Sell
51,535
-16,345
-24% -$790K 0.01% 1074
2015
Q2 		$3.24M Buy
67,880
+1,110
+2% +$47.1K 0.01% 968
2015
Q1 		$2.65M Sell
66,770
-23,011
-26% -$823K 0.01% 1040
2014
Q4 		$2.01M Sell
89,781
-12,719
-12% -$241K 0.01% 1124
2014
Q3 		$1.61M Buy
102,500
+6,684
+7% +$99.9K 0.01% 1239
2014
Q2 		$1.42M Buy
95,816
+8,346
+10% +$118K 0.01% 1318
2014
Q1 		$1.41M Buy
87,470
+43,183
+98% +$739K 0.01% 1301
2013
Q4 		$414K Sell
44,287
-445
-1% -$4.34K ﹤0.01% 2167
2013
Q3 		$506K Sell
44,732
-937
-2% -$12.9K ﹤0.01% 1963
2013
Q2 		$611K Buy
+45,669
New +$561K ﹤0.01% 1706

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

American International Group's NBIX Position: Q2 2024 in Review

American International Group sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 132,511 shares — an estimated $18.3M sold.

American International Group first reported a position in NBIX in Q2 2013 and held it in 43 quarters. The position peaked at $18.3M in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • American International Group reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 132,511 Neurocrine Biosciences shares in Q2 2024, an estimated $18.3M.
  • American International Group first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 43 quarters.
  • American International Group's Neurocrine Biosciences position peaked at $18.3M in Q1 2024.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.